MicroPort Endovascular MedTech Ltd (688016) - Total Liabilities

Latest as of March 2026: CN¥554.42 Million CNY ≈ $81.13 Million USD

Based on the latest financial reports, MicroPort Endovascular MedTech Ltd (688016) has total liabilities worth CN¥554.42 Million CNY (≈ $81.13 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

MicroPort Endovascular MedTech Ltd - Total Liabilities Trend (2016–2025)

This chart illustrates how MicroPort Endovascular MedTech Ltd's total liabilities have evolved over time, based on quarterly financial data. See MicroPort Endovascular MedTech Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

MicroPort Endovascular MedTech Ltd Competitors by Total Liabilities

The table below lists competitors of MicroPort Endovascular MedTech Ltd ranked by their total liabilities.

Company Country Total Liabilities
Abcellera Biologics Inc
NASDAQ:ABCL
USA $369.03 Million
Shanghai Shyndec Pharmaceutical Co Ltd
SHG:600420
China CN¥3.42 Billion
Allied Gold Corporation
NYSE:AAUC
USA $1.27 Billion
FLEX LNG Ltd
NYSE:FLNG
USA $1.90 Billion
Digital China Information Service Co Ltd
SHE:000555
China CN¥8.03 Billion
Compania Nationala de Transport al Energiei Electrice Transelectrica SA
RO:TEL
Romania RON4.14 Billion
Sparebank 1 Nord-Norge
OL:NONG
Norway Nkr124.99 Billion
Fulltech Fiber Glass
TWO:1815
Taiwan NT$8.28 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down MicroPort Endovascular MedTech Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MicroPort Endovascular MedTech Ltd stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 6.94 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.13 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.12 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how MicroPort Endovascular MedTech Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for MicroPort Endovascular MedTech Ltd (2016–2025)

The table below shows the annual total liabilities of MicroPort Endovascular MedTech Ltd from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 CN¥-3.98 Billion
≈ $-582.73 Million
-948.88%
2024-12-31 CN¥469.13 Million
≈ $68.65 Million
+22.60%
2023-12-31 CN¥382.63 Million
≈ $55.99 Million
+51.54%
2022-12-31 CN¥252.49 Million
≈ $36.95 Million
+9.08%
2021-12-31 CN¥231.47 Million
≈ $33.87 Million
+62.90%
2020-12-31 CN¥142.09 Million
≈ $20.79 Million
+58.34%
2019-12-31 CN¥89.74 Million
≈ $13.13 Million
+70.41%
2018-12-31 CN¥52.66 Million
≈ $7.71 Million
+45.29%
2017-12-31 CN¥36.24 Million
≈ $5.30 Million
-44.43%
2016-12-31 CN¥65.22 Million
≈ $9.54 Million
--

About MicroPort Endovascular MedTech Ltd

SHG:688016 China Medical Devices
Market Cap
$1.61 Billion
CN¥10.99 Billion CNY
Market Cap Rank
#7095 Global
#1621 in China
Share Price
CN¥89.18
Change (1 day)
-0.21%
52-Week Range
CN¥87.09 - CN¥121.45
All Time High
CN¥443.37
About

Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft syste… Read more